These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21627406)

  • 21. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
    Wan DH; Fan P; Bai H; Song Q; Liu HW
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
    Glueck CJ; Aregawi D; Agloria M; Winiarska M; Sieve L; Wang P
    Metabolism; 2006 Dec; 55(12):1582-9. PubMed ID: 17142128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
    Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.
    Moradi S; Mollabashi M; Kerman SR
    Gynecol Endocrinol; 2011 Jul; 27(7):480-5. PubMed ID: 20836727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retinol-binding protein in nonobese women with polycystic ovary syndrome.
    Lee JW; Im JA; Lee DC; Lee HR; Shim JY
    Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body fat composition and distribution in women with polycystic ovary syndrome.
    Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
    Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in glycaemic status do not predict weight loss in response to hypocaloric diets in obese patients.
    de Luis DA; Aller R; Izaola O; Gonzalez Sagrado M; Conde R
    Clin Nutr; 2006 Feb; 25(1):117-22. PubMed ID: 16278036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid and lipoprotein profile in women with polycystic ovary syndrome.
    Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S
    Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
    Romualdi D; Costantini B; Campagna G; Lanzone A; Guido M
    Fertil Steril; 2008 Nov; 90(5):1826-33. PubMed ID: 18166189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome.
    Maciel GA; Hayashida SA; da Costa LC; Marcondes JA; da Fonseca AM; Soares JM; Baracat EC
    Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):180-4. PubMed ID: 21530060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical activity is associated with risk factors for chronic disease across adult women's life cycle.
    Woolf K; Reese CE; Mason MP; Beaird LC; Tudor-Locke C; Vaughan LA
    J Am Diet Assoc; 2008 Jun; 108(6):948-59. PubMed ID: 18502225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome.
    Moran LJ; Noakes M; Clifton PM; Tomlinson L; Galletly C; Norman RJ
    J Clin Endocrinol Metab; 2003 Feb; 88(2):812-9. PubMed ID: 12574218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of increased dietary protein-to-carbohydrate ratios in women with polycystic ovary syndrome.
    Sørensen LB; Søe M; Halkier KH; Stigsby B; Astrup A
    Am J Clin Nutr; 2012 Jan; 95(1):39-48. PubMed ID: 22158730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome.
    Nybacka Å; Carlström K; Ståhle A; Nyrén S; Hellström PM; Hirschberg AL
    Fertil Steril; 2011 Dec; 96(6):1508-13. PubMed ID: 21962963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of licorice extract in combination with a low-calorie diet on obesity indices, glycemic indices, and lipid profiles in overweight/obese women with polycystic ovary syndrome (PCOS): a randomized, double-blind, placebo-controlled trial.
    Hooshmandi H; Ghadiri-Anari A; Ranjbar AM; Fallahzadeh H; Hosseinzadeh M; Nadjarzadeh A
    J Ovarian Res; 2024 Jul; 17(1):157. PubMed ID: 39080737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study.
    Bagis T; Gokcel A; Zeyneloglu HB; Tarim E; Kilicdag EB; Haydardedeoglu B
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4536-40. PubMed ID: 12364431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.